BackLyell Immunopharma Overview
Lyell Immunopharma Inc

Lyell Immunopharma Target Price

See Lyell Immunopharma's analyst price targets ($34) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$9.26

Average Target Price

$34.00267.2% upside

1 analysts in the last 4 months

High: $34 | Low: $34

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-14RBC Capital$34267.2% upsideOpen
2026-06-03Needham$45386% upsideOpen
2026-04-30Robert W. Baird$49429.2% upsideOpen
2026-04-10Needham$44375.2% upsideOpen
2025-12-09H.C. Wainwright$45386% upsideOpen
2025-11-24H.C. Wainwright$20116% upsideOpen
2024-10-30Bank of America SecuritiesGeoff Meacham$189.2% downsideOpen
2022-11-14Morgan Stanley$724.4% downsideOpen
2022-05-24Goldman Sachs$1229.6% upsideOpen

Lyell Immunopharma (LYEL) FAQ

The latest target price for LYEL is $34. Investors often review this figure alongside Lyell Immunopharma's historical trend and sector peers before judging valuation or financial health.

Lyell Immunopharma trades near $9.26 while the consensus target sits at $34 (267.2% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting LYEL's target price ($34), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lyell Immunopharma's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.